Global Factor IX Deficiency Treatment Market 2017-2021 - Product Image

Global Factor IX Deficiency Treatment Market 2017-2021

  • ID: 4143796
  • Report
  • Region: Global
  • 70 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Biogen
  • CSL Behring
  • Novo Nordisk
  • Pfizer
  • Shire
  • MORE
About Factor IX Deficiency Treatment

The global factor IX deficiency treatment market is characterized by the presence of various therapeutic products provided by some of the top vendors such as Shire, CSL Behring, Novo Nordisk, Biogen, and Pfizer. The adoption rate of therapeutics has undergone a paradigm shift toward the introduction of gene therapy, which will lead to the development of new products. However, the low penetration rate of recombinant therapy in developing countries is the current challenge in the market. This low penetration rate in developing countries is due to the higher cost of recombinant drugs, limited disease knowledge, and a shortage of treatment supplies. Nevertheless, the market has observed a positive side of individuals adopting recombinant drugs is expected to improve the diagnosis and treatment rates for hemophilia B in the medium- to long-term.

The analysts forecast the global factor IX deficiency treatment market to grow at a CAGR of 5.12% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global factor IX deficiency treatment market for 2017-2021. To calculate the market size, the report considers the revenue generated from sales of factor IX products in the different diseases.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Factor IX Deficiency Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Biogen
- CSL Behring
- Novo Nordisk
- Pfizer
- Shire

Market drivers
- Growing pipeline with increased focus to meet unmet demand.
- For a full, detailed list, view the full report

Market challenges
- Emerging price war in the industry.
- For a full, detailed list, view the full report

Market trends
- Increase in investments in the production and discovery.
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the Key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Biogen
  • CSL Behring
  • Novo Nordisk
  • Pfizer
  • Shire
  • MORE
PART 01: Executive summary

PART 02: Scope of the report
  • Market overview
  • Assumptions
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
  • Highlights
PART 05: Disease overview

PART 06: Pipeline analysis

PART 07: Market landscape
  • Market overview
  • Five forces analysis
PART 08: Market segmentation by disease type
  • Global hemophilia B drugs market
  • Global hemophilia B inhibitors market
PART 09: Market segmentation by type of therapy
  • Recombinant therapies
  • Plasma-derived therapies
PART 10: Market segmentation by type of disease management
  • Prophylaxis
  • On-demand therapy
  • Inhibitor therapy
PART 11: Geographical segmentation
  • Factor IX drugs market in Americas
  • Factor IX drugs market in EMEA
  • Factor IX drugs market in APAC
PART 12: Market drivers
  • Shifting toward half-life drugs
  • Special designations promote novel launches
  • Growing pipeline with increased focus to meet unmet demand
PART 13: Impact of drivers

PART 14: Market challenges
  • Emerging price war in the industry
  • Low penetration rate
  • Lack of complete remission
  • High entry barriers
PART 15: Impact of drivers and challenges

PART 16: Market trends
  • Increasing focus on gene therapy
  • Increase in investments in the production and discovery
  • Strategic initiatives should lead to consolidation
PART 17: Vendor landscape
  • Competitive scenario
PART 18: Key vendor analysis
  • Biogen
  • CSL Behring
  • Novo Nordisk
  • Pfizer
  • Shire
PART 19: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Process of gene therapy
Exhibit 03: Key buying criteria and customer segments of global factor IX deficiency treatment market
Exhibit 04: Key customer segments of factor IX deficiency treatment market
Exhibit 05: Pipeline analysis
Exhibit 06: Key clinical trials
Exhibit 07: Global factor IX deficiency treatment market snapshot
Exhibit 08: Global factor IX deficiency treatment market by revenue 2016-2021 ($ millions)
Exhibit 09: Five forces analysis
Exhibit 10: Hemophilia B drugs market for global factor IX deficiency treatment market 2016-2021 ($ millions)
Exhibit 11: Hemophilia B inhibitors market for global factor IX deficiency treatment market 2016-2021 ($ millions)
Exhibit 12: Global factor IX recombinant therapies market 2016-2021 ($ millions)
Exhibit 13: Global factor IX plasma-derived therapies market 2016-2021 ($ millions)
Exhibit 14: Segmentation of factor IX drugs market by type of disease management 2016
Exhibit 15: Factor IX deficiency treatment market in Americas 2016-2021 ($ millions)
Exhibit 16: Factor IX deficiency treatment market in EMEA 2016-2021 ($ millions)
Exhibit 17: Factor IX deficiency treatment market in APAC 2016-2021($ millions)
Exhibit 18: Launch of half-life drugs for treatment of factor IX deficiency
Exhibit 19: Special designation to factor IX drugs in 2016
Exhibit 20: A few late-stage (Phase III) factor IX drugs
Exhibit 21: Impact of drivers
Exhibit 22: Impact of drivers and challenges
Exhibit 23: Competitive structure of global factor IX deficiency treatment market 2016
Exhibit 24: Competitive analysis of global factor IX deficiency treatment market
Exhibit 25: Market share analysis 2016
Exhibit 26: Market penetration of factor IX vendors 2016
Exhibit 27: Biogen: Key highlights
Exhibit 28: Biogen: Strength assessment
Exhibit 29: Biogen: Strategy assessment
Exhibit 30: Biogen: Opportunity assessment
Exhibit 31: Year-over-year (YoY) revenue of ALPROLIX 2014-2016 ($ millions)
Exhibit 32: CSL Behring: Key highlights
Exhibit 33: CSL Behring: Strength assessment
Exhibit 34: CSL Behring: Strategy assessment
Exhibit 35: CSL Behring: Opportunity assessment
Exhibit 36: Novo Nordisk: Key highlights
Exhibit 37: Novo Nordisk: Strength assessment
Exhibit 38: Novo Nordisk: Strategy assessment
Exhibit 39: Novo Nordisk: Opportunity assessment
Exhibit 40: Pfizer: Key highlights
Exhibit 41: Pfizer: Strength assessment
Exhibit 42: Pfizer: Strategy assessment
Exhibit 43: Pfizer: Opportunity assessment
Exhibit 44: Shire: Key highlights
Exhibit 45: Shire: Strength assessment
Exhibit 46: Shire: Strategy assessment
Exhibit 47: Shire: Opportunity assessment
Exhibit 48: Shire: YoY revenue comparison of RIXUBIS 2014 and 2015 ($ millions)
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Biogen
  • CSL Behring
  • Novo Nordisk
  • Pfizer
  • Shire
  • MORE
New Report Released: – Global Factor IX Deficiency Treatment Market 2017-2021

The author of the report recognizes the following companies as the key players in the global factor IX deficiency treatment market: Biogen, CSL Behring, Novo Nordisk, Pfizer, and Shire.

Commenting on the report, an analyst from the research team said: “One trend in market is increasing focus on gene therapy. Gene therapy uses genetic science to treat and prevent disease. Gene therapy is being tested for the treatment of rare disease. The market is increasing focus toward the development of gene therapy products for factor IX deficiency or hemophilia B. The growing focus of such therapy is due to its ability to cure the disease quickly compared with conventional therapies. The available treatment options include factor IX replacement therapies, which on frequent usage leads to patient resistant to the treatment regimen and increases risks of infections. To overcome these challenges, pharmaceutical companies are developing alternatives based on gene therapy. These candidates offer a permanent cure for hemophilia by direct delivery of the healthy gene producing human factor IX into the individuals' liver cells. This help people with hemophilia B allowing them to produce their clotting factor, lessening the need for or reducing the number of weekly infusions.”

According to the report, one driver in market is shifting toward half-life drugs. Half-life is the reduction of time required for a drug by one-half to get concentrated into the body. The introduction of half-life drugs is a significant improvement in the field of hemophilia B. The less frequent dosing means potentially fewer infusion reactions and lesser opportunities to produce inhibitors, which ultimately leads to increased patient adherence. Thus, it has been observed that the increasing focus on launching drugs with extended half-life has been enabling to increase the adoption rates.

Further, the report states that one challenge in market is emerging price war in the industry. Hemophilia is a hereditary disorder that prevents blood from clotting due to lack of a clotting factor protein in the blood. Individuals with severe hemophilia require larger and more frequent doses of blood-clotting factors. Globally, about one in 25,000 men are born with hemophilia B each year. Less number of approved therapies and huge costs associated with the treatment remains one of the significant challenges to this market. However, a few recent launches indicate that to make the product cost competitive, the vendors are launching at a moderate pricing to suit the payers budget. This incidentally will result in a price war among the vendors, which will create value erosion scenario for the market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Biogen
  • CSL Behring
  • Novo Nordisk
  • Pfizer
  • Shire
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll